Large B-cell Lymphoma

Golcadomide in B-Cell Lymphoma

Dec 15, 2023

Harmony in Treatment: GOLCA (golcadomide) Reveals Favorable Safety Profile and Seamless Integration with R-CHOP for Untreated Aggressive B-Cell Lymphoma

ALLO-647 for Lymphodepletion

Dec 15, 2023

ALLO-647 Integration in Lymphodepletion: Paving the Way for Enduring Responses and Safe CAR T cell Therapy Advancements

Golcadomide-Rituximab Combo in DLBCL Patient

Dec 15, 2023

Golcadomide and Rituximab Combo Unveils Promising Efficacy in Heavily Pretreated Relapsed/Refractory DLBCL

Analysis of the Phase 2 PILOT Study

Dec 12, 2023

Liso-cel (lisocabtagene maraleucel) Shines in Second-Line, Yielding Long-Lasting Complete Responses for Non-Transplant Eligible LBCL Patients

Pharma News Updates Merck, Regeneron, Provention, Ardelyx, AbbVie

Nov 22, 2022

FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL

Pharma News for Ipsen, BioMarin and AbbVie

Jun 28, 2022

Ipsen to Buy Epizyme; BioMarin’s Gene Therapy for Hemophilia; AbbVie’s Qulipta for Chronic Migraine; FDA Approves Breyanzi for R/R LBCL; NDA Filed for Elacestrant in ER+/HER2- Breast Cancer; EU Approval to Enhertu for Breast Cancer; FDA Approves Novartis’ BRAF-positive Tumor Combination; GSK’s Hepatitis B Vaccine, Bepirovirsen

pharma-news-for-sandoz-agios-organon-bms-sanofi-bayer-lilly

Feb 22, 2022

Sandoz’s Generic Revlimid; Agios’ Pyrukynd; Organon Announces 4Q & Full-year Earnings Report; BMS’ CAR-T Drug Breyanzi; Sanofi & Regeneron’s Dupixent Trial; AZ & Daiichi’s Drug Enhertu; Bayer’s Drug Kerendia; Lilly Releases Mirikizumab Data

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper